| UCB PHARMA, S.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129219 | Antibody Molecules Which Bind Human IL-17 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules. | 05-24-2012 |
| 20120095005 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors - A series of substituted pyrazolo[1,5-α][1,3,5]triazine and pyrazolo[1,5-αj-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 04-19-2012 |
| 20120094297 | Method For Producing Protein - The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell. | 04-19-2012 |
| 20120077815 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors - A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 03-29-2012 |
| 20120040401 | Method For Producing Proteins - The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component of the multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second encoding polynucleotide sequences and the multimeric protein is an antibody or fragment thereof and each encoding polynucleotide sequence encodes one or more antibody domains or fragments thereof. | 02-16-2012 |
| 20120040006 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 02-16-2012 |
| 20120034656 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 02-09-2012 |
| 20120029188 | Substituted Aniline Derivatives - The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections. | 02-02-2012 |
| 20110313138 | Method for Producing Proteins - This invention provides a method for obtaining a recombinant antibody with a desired function, comprising: (a) providing a population of antibody-forming cells suspected of containing at least one cell capable of producing an antibody exhibiting the desired function; (b) generating one or more transcriptionally active recombinant linear polynucleotides from the antibody forming cells obtained in step (a) wherein each transcriptionally active recombinant linear polynucleotide comprises a polynucleotide sequence encoding a variable domain of an antibody produced by an antibody-forming cell obtained in step (a) and one or more transcription regulatory elements; (c) expressing a recombinant antibody using one or more of the transcriptionally active recombinant linear polynucleotides generated in step (b); (d) screening the recombinant antibody produced by step (c) for the desired function; and (e) optionally repeating steps (b), (c) and (d) to identify a recombinant antibody exhibiting the desired function. | 12-22-2011 |
| 20110305702 | EPITOPES - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 12-15-2011 |
| 20110281929 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-17-2011 |
| 20110275857 | Antibody-Guided Fragment Growth - The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from anti-body-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein. | 11-10-2011 |
| 20110275693 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-10-2011 |
| 20110274762 | Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivate - The present invention relates to a pharmaceutical composition comprising Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation made of granules containing the active ingredient in their inner core. | 11-10-2011 |
| 20110262443 | Epitopes Of Il-17a And Il-17f And Antibodies Specific Thereto - The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them. | 10-27-2011 |
| 20110250282 | Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivative - The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 10-13-2011 |
| 20110201630 | Fused Pyridine Derivatives as Kinase Inhibitors - A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 08-18-2011 |
| 20110184152 | Biological Products - A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab′ fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween. | 07-28-2011 |
| 20110172191 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 07-14-2011 |
| 20110105508 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS - A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 05-05-2011 |
| 20110098300 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals, useful for the treatment and prevention of diseases or pathological conditions of the central nervous system including mild-cognitive impairments, Alzheimer's disease, learning and; memory disorders, cognitive disorders, attention deficit disorder, attention-deficit hyperactivity disorder, Parkinson's disease, schizophrenia, dementia, depression, epilepsy, seizures, convulsions, sleep/wake and arousal/vigilance disorders such as hypersomnia and narcolepsy, pain and/or obesity. | 04-28-2011 |
| 20110097342 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 04-28-2011 |
| 20110091547 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 04-21-2011 |
| 20110064808 | EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect. | 03-17-2011 |
| 20110064807 | EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system. | 03-17-2011 |
| 20110021786 | Pharmaceutical Solutions, Process of Preparation and Therapeutic Uses - The present invention concerns a stable pharmaceutical solution, a process of the preparation thereof and therapeutic uses thereof. | 01-27-2011 |
| 20110021558 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 01-27-2011 |
| 20110014271 | Substituted Aniline Derivatives - The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections. | 01-20-2011 |
| 20110003785 | Fused Thiazole Derivatives As Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-06-2011 |
| 20100310564 | Method for the Treatment of Glomerulonephritis - The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide. | 12-09-2010 |
| 20100305116 | Compounds Comprising a Cyclobutoxy Group - The present invention relates to compounds comprising a cyclobutoxy group, processes for preparing them, phar-maceutical compositions comprising said compounds and their use as pharmaceuticals. | 12-02-2010 |
| 20100305066 | Fused Thiophene Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 12-02-2010 |
| 20100298310 | Thiazole Derivatives as Kinase Inhibitors - A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 11-25-2010 |
| 20100298289 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS - The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 11-25-2010 |
| 20100292505 | Sulfanyl Derivatives And Their Use As Synthesis Intermediates - The present application relates to sulfanyl derivatives of formula (I) and to their use as synthesis intermediates, especially for the preparation of the pharmaceutically active compound mesna. Formula (I), wherein X is O or N—C(NH)NH | 11-18-2010 |
| 20100292188 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals. | 11-18-2010 |
| 20100285530 | E.Coli Host Cells with Modified Phos/Psts Periplasmic Phosphate-binding Proteins, and Method of Manufacturing Recombinant Fabs - The present invention provides an | 11-11-2010 |
| 20100266609 | Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 10-21-2010 |
| 20100240728 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-23-2010 |
| 20100239582 | Dual Specificity Antibody Fusions - The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest. | 09-23-2010 |
| 20100222326 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders - The present invention relates to new compounds, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 09-02-2010 |
| 20100179185 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof - The present invention concerns novel 3-aminothienopyridinone derivatives of the formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 07-15-2010 |
| 20100179124 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 07-15-2010 |
| 20100168077 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof - The present invention concerns 2-amino pyridine derivatives of formula 1 processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 07-01-2010 |
| 20100158913 | Antibody Molecules Having Specificity for Human IL-1B - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 06-24-2010 |
| 20100137302 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 06-03-2010 |
| 20100093977 | Altered Antibodies - This invention relates to engineering of antibodies and more specifically provides altered antibodies of the IgG class to which one or more effector molecules are attached. The invention further relates to methods for the production of such conjugated antibodies. | 04-15-2010 |
| 20100086538 | Antibody Molecules Which Bind to Human IL-17 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 04-08-2010 |
| 20100069375 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses - The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion. | 03-18-2010 |
| 20100069361 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 03-18-2010 |
| 20100036091 | ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 02-11-2010 |
| 20100035863 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions - The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals. | 02-11-2010 |
| 20100016795 | SYSTEMS FOR ADMINISTERING MEDICATION - The autoinjector systems disclosed herein provide in part devices for allowing patients with reduced joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a housing, a syringe assembly slidably mounted on the housing, and a needle cap releasably engaged to the housing, where the cap includes a protruding pocket for receiving a needle cap remover. | 01-21-2010 |
| 20100015665 | ANTIBODIES AND DIAGNOSTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 01-21-2010 |
| 20100009969 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands - The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H | 01-14-2010 |
| 20090326203 | Framework Selection - The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks. | 12-31-2009 |
| 20090312333 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses - The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 12-17-2009 |
| 20090304713 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 12-10-2009 |
| 20090304696 | Single Chain FC Polypeptides - The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain. | 12-10-2009 |
| 20090264411 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS - A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 10-22-2009 |
| 20090239263 | Expression Control Using Antibody Expression Optimisation Sequences - The present invention provides a dicistronic message for producing an antibody molecule, in which the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain, characterised in that the dicistronic message comprises a sequence selected from AEOS1 (SEQ ID NO:1), AEOS2 (SEQ ID NO:2), AEOS3 (SEQ ID NO:3), AEOS4 (SEQ ID NO: 4), AEOS5 (SEQ ID NO:5), AEOS6 (SEQ ID NO:6), AEOS7 (SEQ ID NO:7), AEOS8 (SEQ ID NO:8), AEOS9 (SEQ ID NO:9), AEOS1O (SEQ ID NO:10) and AEOS1 1 (SEQ ID NO:11). | 09-24-2009 |
| 20090221828 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives - A process for preparing 1-halo-2,7-naphthyridinyl derivatives is described (I), wherein X is Cl or Br; which process comprises the following steps: (i) reaction of a 3-cyano-4-methylpyridine derivative of formula (A): with a compound of formula (II), in the presence of an N,N-dimethylformamide diC | 09-03-2009 |
| 20090209498 | Methods of Treatment Using CCA1 Inhibitors - Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor. | 08-20-2009 |
| 20090186914 | Phenylalanine Enamide Derivatives - Phenylalanine enamide derivatives of formula (1) are described: | 07-23-2009 |
| 20090149437 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 06-11-2009 |
| 20090131508 | Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug - The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies. | 05-21-2009 |
| 20090123944 | Bioassays - The invention relates to vectors encoding bioassay receptors and in vitro bioassays using said bioassay receptors for assessing compounds of interest. In particular, the bioassays provide a generic platform for the comparison of binding of different ligands to their respective receptors or binding partners in the presence and/or absence of a compound of interest. | 05-14-2009 |
| 20090117126 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 05-07-2009 |
| 20090075398 | Method for Obtaining Antibodies - A method of obtaining at least one recombinant antibody with improved affinity for a selected antigen from a family of antibodies which bind the selected antigen comprising: a) obtaining a family of two or more antibodies which bind the same antigen in which the VH CDR3 amino acid sequence of each antibody in the family is the same length and greater than 60% identical at the amino acid level; b) re-pairing the VH region of an antibody obtained in step (a) with the VL region from a different antibody obtained in step (a) to produce a new recombinant antibody; and c) screening the recombinant antibody produced in step (b) and selecting said antibody if it has improved affinity for the selected antigen compared to any one of the antibodies obtained in step (a). | 03-19-2009 |
| 20090023708 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals. | 01-22-2009 |
| 20090018148 | Xanthine Derivatives, Processes For Preparing Them And Their Uses - The present invention concerns xanthine derivatives, having formula (I), processes for preparing them, pharmaccutical compositions containing them and their use as pharmaceuticals. | 01-15-2009 |
| 20090012313 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses - The present invention relates to 3-carboxy-2-oxo-1-pyrrolidine derivatives of formula (I), geometrical isomers, enantiomers, diastereoisomers, pharmaceutically acceptable salts and all possible mixtures thereof, and processes using them. | 01-08-2009 |
| 20090012147 | Indolone Derivatives, Processes For Preparing Them And Their Uses - The present invention relates to indolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 01-08-2009 |
| 20080306246 | Process for Attaching Effector Molecules to Proteins - The present invention provides a process for attaching one or more effector molecules to one or more cysteines in a protein comprising: a) activating one or more cysteines in the protein by diafiltering the protein against a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds and b) reacting the treated protein with an effector molecule. | 12-11-2008 |
| 20080306060 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 12-11-2008 |
| 20080275046 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H | 11-06-2008 |
| 20080269489 | Pyroglutamate Salts and Their Use in the Optical Resolution of Intermediates for the Synthesis of Dextrocetirizine and Levocetirizine - The present invention relates to (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide-(S)-pyrrolidone-5-carboxylic acid salt; (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide-(S)-pyrrolidone-5-carboxylic acid salt; (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide-(R)-pyrrolidone-5-carboxylic acid salt; or (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxycetamide-(R)-pyrrolidone-5-carboxylic salt. The present invention relates also to a process for preparing (S)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide (I) and (R)-2-[4-(4-chlorobenzhydryl) piperazin-1-yl]-ethoxyacetamide (II) by chemical resolution of a mixture. These compounds are respectively intermediates for the synthesis of dextrocetirizine and levocetirizine. | 10-30-2008 |
| 20080269466 | Modified Antibody Fragments - The present invention relates to a new class of modified antibody fragments. The present invention provides an antibody fragment to which one or more effector molecules is attached characterized in that the native interchain disulphide bond between the heavy (CHI) and light (CL) chain constant regions is absent and the heavy chain (CHI) and light chain (CL) constant regions are linked by an interchain disulphide bond between a pair of engineered cysteines, one in the light chain constant (CL) region and the other in the heavy chain constant (CHI) region. | 10-30-2008 |
| 20080269465 | BIOLOGICAL PRODUCTS - There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα. | 10-30-2008 |
| 20080269316 | Pharmaceutical Compositions Comprising Levetiracetam and Process for Their Preparation - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation. | 10-30-2008 |
| 20080220005 | Comb Polymers - The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B | 09-11-2008 |
| 20080207907 | Process For Pd-Catalysed C-N Coupling In Specific Solvent Systems - The invention relates to a novel process for the Pd catalysed formation of C—N bonds between an aryl halide or an aryloxysulphonyl compound and an amine in specific solvent systems, and also to the use of these solvent systems for C—N couplings. | 08-28-2008 |
